Display options
Cite
Ferret-Sena V, Maia E Silva A, Sena A, et al. Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR Res. 2016;2016:5716415doi: 10.1155/2016/5716415.
Ferret-Sena, V., Maia E Silva, A., Sena, A., Cavaleiro, I., Vale, J., Derudas, B., Chinetti-Gbaguidi, G., & Staels, B. (2016). Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR research, 20165716415. https://doi.org/10.1155/2016/5716415
Ferret-Sena, Véronique, et al. "Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis." PPAR research vol. 2016 (2016): 5716415. doi: https://doi.org/10.1155/2016/5716415
Ferret-Sena V, Maia E Silva A, Sena A, Cavaleiro I, Vale J, Derudas B, Chinetti-Gbaguidi G, Staels B. Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR Res. 2016;2016:5716415. doi: 10.1155/2016/5716415. Epub 2016 Dec 18. PMID: 28077943; PMCID: PMC5203914.
Copy Download .nbib Format: NLM
Share it on

PPAR Res. 2016;2016:5716415. doi: 10.1155/2016/5716415. Epub 2016 Dec 18.

Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis.

PPAR research

Véronique Ferret-Sena, Alexandra Maia E Silva, Armando Sena, Inês Cavaleiro, José Vale, Bruno Derudas, Giulia Chinetti-Gbaguidi, Bart Staels

Affiliations

  1. Interdisciplinary Centre of Research Egas Moniz (CiiEM), Caparica, Portugal.
  2. Interdisciplinary Centre of Research Egas Moniz (CiiEM), Caparica, Portugal; Neurology Service, Hospital dos Capuchos, Centro Hospitalar Lisboa Central, Lisboa, Portugal.
  3. Department of Neurology, Hospital Beatriz Angelo, Loures, Portugal.
  4. University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.
  5. University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France; University of Côte d'Azur, CHU, CNRS, Inserm, IRCAN, Nice, France.

PMID: 28077943 PMCID: PMC5203914 DOI: 10.1155/2016/5716415

Abstract

Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression in MS patients. We analyzed gene expression of PPAR in peripheral blood mononuclear cells (PBMC) as well as blood inflammatory markers in women with MS previously medicated with first-line immunomodulators (baseline) and after NTZ therapy. No differences in PPAR

Conflict of interest statement

The authors declare that they have no competing interests.

References

  1. Brain Behav Immun. 2014 Jan;35:176-81 - PubMed
  2. J Neurochem. 2008 Oct;107(2):497-509 - PubMed
  3. J Neuroimmunol. 2009 Jun 25;211(1-2):124-30 - PubMed
  4. Diabetes. 2007 Jun;56(6):1662-70 - PubMed
  5. Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1050-9 - PubMed
  6. J Neuroimmunol. 2005 Jan;158(1-2):231-9 - PubMed
  7. Transl Neurosci. 2012 Feb 1;3(3):288-293 - PubMed
  8. Neurosci Lett. 2013 Oct 25;554:131-4 - PubMed
  9. J Neurol. 2010 Oct;257(10):1703-7 - PubMed
  10. Brain. 2012 May;135(Pt 5):1586-605 - PubMed
  11. J Exp Med. 2010 Aug 2;207(8):1599-608 - PubMed
  12. Neurol Neuroimmunol Neuroinflamm. 2016 Mar 03;3(2):e210 - PubMed
  13. Nucleic Acids Res. 2015 May 26;43(10):5033-51 - PubMed
  14. Eur J Neurol. 2009 Apr;16(4):528-36 - PubMed
  15. J Immunol. 2005 Oct 15;175(8):4948-55 - PubMed
  16. Circ Res. 2002 Feb 22;90(3):348-55 - PubMed
  17. J Biol Chem. 2012 Oct 5;287(41):34134-48 - PubMed
  18. Neurology. 2009 Jun 2;72(22):1922-30 - PubMed
  19. Biosci Trends. 2014 Apr;8(2):120-5 - PubMed
  20. J Exp Med. 2007 Feb 19;204(2):321-30 - PubMed

Publication Types